1. Use of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide in combination with one or more immunotherapeutic agents, in the manufacture of a medicament for treating a tumour, wherein the conjugate induces the formation of ectopic lymph nodes in the tumour, normalizes the tumour vasculature and/or improves tumour vessel function.

2. The use of claim 1, wherein the LIGHT polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or is encoded by the nucleotide sequence set forth in SEQ ID NO:2.

3. The use of claim 1 or 2, wherein the tumour homing peptide is selected from an RGR-containing peptide, a CGKRK-containing peptide and a CREKA-containing peptide

4. The use of claim 3, wherein the tumour homing peptide is an RGR-containing peptide.

5. The use of claim 4, wherein the RGR-containing peptide comprises the amino acid sequence CRGRRSTG (SEQ ID NO:5).

6. The use of claim 4 or 5, wherein the RGR-containing peptide is conjugated at the C-terminal of the LIGHT polypeptide.

7. The use of any one of claims 1 to 6, wherein the medicament is to be administered to the subject prior to, concomitantly with, or subsequent to the one or more immunotherapeutic agents.

8. The use of any one of claims 1 to 7, wherein said one or more immunotherapeutic agents comprises one or more immune checkpoint inhibitors.

9. The use of claim 8, wherein said one or more immune checkpoint inhibitors comprise anti-CTLA4 antibodies and/or anti-PD-1 antibodies.

10. The use of any one claims 1 to 9, wherein the medicament is to be administered with a tumour-specific vaccine.

11. The use of claim 9 or 10, wherein the medicament is to be administered prior to the one ore antibodies or tumour-specific vaccine.

12. The use of any one of claims 1 to 11, wherein normalization of the tumour vasculature is characterised by induction of pericyte contractility.

13. The use of any one of claims 1 to 11, wherein the normalization of tumour vasculature and/or improvement of tumour vessel function comprises or results in one or more of restoration of tumour blood vessel integrity, a reduction in leakiness of tumour blood vessels and/or an increase in tumour perfusion.

14. Use of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide in combination with one or more immunotherapeutic agents, in the manufacture of a medicament for increasing or extending the survival time of a cancer patient.

15. The use of claim 14, wherein the LIGHT polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or is encoded by the nucleotide sequence set forth in SEQ ID NO:2.

16. The use of claim 14 or 15, wherein the tumour homing peptide is selected from an RGR-containing peptide, a CGKRK-containing peptide and a CREKA-containing peptide.

17. The use of claim 16, wherein the tumour homing peptide is an RGR-containing peptide.

18. The use of claim 17, wherein the RGR-containing peptide comprises the amino acid sequence CRGRRSTG (SEQ ID NO:5).

19. The use of claim 17 or 18, wherein the RGR-containing peptide is conjugated at the C-terminal of the LIGHT polypeptide.

20. The use of any one of claims 14 to 19, wherein the medicament is to be administered to the subject prior to, concomitantly with, or subsequent to the one or more immunotherapeutic agents.

21. The use of any one of claims 14 to 20, wherein said one or more immunotherapeutic agents comprises one or more immune checkpoint inhibitors.

22. The use of claim 21, wherein said one or more immune checkpoint inhibitors comprise anti-CTLA4 antibodies and/or anti-PD-1 antibodies.

23. The use of any one claims 14 to 22, wherein the medicament is to be administered with a tumour-specific vaccine.

24. The use of claim 22 or 23, wherein the medicament is to be administered prior to the one or more antibodies or tumour-specific vaccine.